Halozyme Therapeutics, Inc. (HALO)

NMS – Real Time Price. Currency in USD

100.66

-1.96 (-1.91%)

Market open: Aug 12, 2026, 1:43 PM EDT

104.19

+1.57 (1.53%)

Previous after-hours: Aug 11, 2026, 7:36 PM EDT

Stock details

Previous close: 102.62$
Day's range: 101.81 - 104.78$
52-week range: 61.23 - 104.78$
Volume: 2 846 031
Average volume: 2 771 674
Beta: 0.83
EPS (TTM): 3.52
PE ratio (TTM): 30.66
Forward P/E: 12.29
Market cap: 11 647 165 184
Shares outstanding: 113 498 004
Dividend yield: N/A
Next earnings date: 2026-11-09
Sector: Healthcare
Industry: Biotechnology

About the company

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company’s products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as smal... read more

CEO: Helen Torley
Country: United States
IPO Date
Employees: 423
Fiscal Year End: January - December
Website: https://halozyme.com

Revenue Breakdown

Proprietary Enzymes, Devices, Hypercon Technology, and the Surf Bio Technology / 100.00%

News

No Data

There are no news for this stock.

Chart: HALO

Loading Chart...

Overall Score

6.9 / 1069%

Octagon View

Strength & Weakness

Total debt $2.1B significantly exceeds cash reserves ($163.1M), raising financial stability concerns

Total current assets $933.0M exceed Total current liabilities $344.4M, highlighting excellent liquidity

Debt-to-equity ratio (15.0) far exceeds the industry average, reflecting over-leverage

Interest coverage ratio (51x) indicates the company easily manages its debt payments

The company generates positive free cash flow $236.7M, supporting its financial health

Financial Strength

NAME	RATIO	INDUSTRY	SCORE
Current ratio	2.71	6.05	10
Quick ratio	2.31	5.63	10
Debt to Equity	14.95	0.30	2.0
Debt to Assets	0.83	1.04	2.0
Interest coverage	51.48	-16.91	10
Weighted average score			6.8

Debt to Assets

Financial

Values in USD
(B=Billions, M=Millions, K=Thousands)

Values in USD (B=Billions, M=Millions, K=Thousands)

METRIC	2022	2023	2024	2025	TTM
Total Revenue	660M	829M	1.02B	1.40B	1.66B
Gross Profit	478M	563M	785M	1.09B	1.27B
Operating Income	289M	338M	551M	816M	944M
Net Income	202M	282M	444M	317M	414M
EBITDA	339M	422M	633M	904M	1.06B

Current Ratio

Revenue & Net Income

Cashflow

Margin Ratios

Profitability

NAME	RATIO	INDUSTRY	SCORE
Gross margin %	77.40	-11.73	10
Operating margin %	59.80	-24.60	10
Net margin %	47.80	-172.20	10
EBITDA margin %	66.87	-201.27	10
Cash flow margin %	50.08	-156.39	10
Weighted average score			10.0

Net Margin

Effectiveness

NAME	RATIO	INDUSTRY	SCORE
ROA	18.16	-57.97	9.0
ROE	137.79	-63.56	10
ROIC	22.47	-42.57	10
ROCE	11.66	-71.10	7.0
Weighted average score			9.0

Estimated EPS vs Actual EPS

Forecast

NAME	REVENUE GROWTH	EPS GROWTH	SCORE
Current quarter	36.13	30.4	10
Next quarter	18.05	1160.12	9.5
Current year	31.69	101.27	10
Next year	11.5	23.43	8.5
Weighted average score			9.5

Analyst Rating

Growth

NAME	REVENUE	NET INCOME	EPS	FCF	SCORE
Q/Q	27.68	53.23	42.5	34.24	10
Y/Y	47.67	39.21	48.05	141.18	10
3y average	28.54	22.8	47.73	40.58	10
5y average	40.04	46.11	59.37	112.69	10
Weighted average score					10

Revenue Growth Rate vs. Industry

Valuation

NAME	RATIO	INDUSTRY	SCORE
P/E	30.09	-5.25	4.0
PEG (5yr expected)	N/A	0.27	1.0
P/S	7.54	64.66	6.4
P/B	81.12	2.96	1.6
Weighted average score			3.3

DCF Model

DCF Model Period5 years

Discount rate8.47%

Perpetual growth rate3%

Revenue 5 year CAGR23.71%

FCF 5 year CAGR4

Fair value126.3$

Stock price101.915$

Dividend

NAME	CURRENT	INDUSTRY	SCORE
Dividend yield	0.00	N/A	1.0
Payout ratio	0.00	N/A	1.0
5-year dividend growth rate	N/A	N/A	1.0
Years of dividend increase	N/A	N/A	1.0
Weighted average score			1.0

Fair Value

$126.3

UndervaluedStock priceOvervalued

$101.915

Economic Moat

NAME	SCALE	SCORE
Market share	Medium	6.0
Intangible assets	Wide	8.0
Switching costs	Wide	8.0
Network effect	Narrow	2.0
Economies of scale	Medium	6.0
Weighted average score		6.0

About the company

CEO

Helen Torley

Country

United States

IPO Date

Employees

423

Fiscal Year End

January - December

Website

https://halozyme.com

NAME

RATIO

INDUSTRY

5Y TREND

SCORE

Current ratio

2.71

6.05

Quick ratio

2.31

5.63

Debt to Equity

14.95

0.30

2.0

Debt to Assets

0.83

1.04

2.0

Interest coverage

51.48

-16.91

Weighted average score

6.8

METRIC

2022

2023

2024

2025

TTM

Total Revenue

660M

829M

1.02B

1.40B

1.66B

Gross Profit

478M

563M

785M

1.09B

1.27B

Operating Income

289M

338M

551M

816M

944M

Net Income

202M

282M

444M

317M

414M

EBITDA

339M

422M

633M

904M

1.06B

NAME

RATIO

INDUSTRY

5Y TREND

SCORE

Gross margin %

77.40

-11.73

Operating margin %

59.80

-24.60

Net margin %

47.80

-172.20

EBITDA margin %

66.87

-201.27

Cash flow margin %

50.08

-156.39

Weighted average score

10.0

NAME

RATIO

INDUSTRY

5Y TREND

SCORE

ROA

18.16

-57.97

9.0

ROE

137.79

-63.56

ROIC

22.47

-42.57

ROCE

11.66

-71.10

7.0

Weighted average score

9.0

NAME

REVENUE GROWTH

EPS GROWTH

SCORE

Current quarter

36.13

30.4

Next quarter

18.05

1160.12

9.5

Current year

31.69

101.27

Next year

11.5

23.43

8.5

Weighted average score

9.5

NAME

REVENUE

NET INCOME

EPS

FCF

SCORE

Q/Q

27.68

53.23

42.5

34.24

Y/Y

47.67

39.21

48.05

141.18

3y average

28.54

22.8

47.73

40.58

5y average

40.04

46.11

59.37

112.69

Weighted average score

NAME

RATIO

INDUSTRY

5Q TREND

SCORE

P/E

30.09

-5.25

4.0

PEG (5yr expected)

N/A

0.27

1.0

P/S

7.54

64.66

6.4

P/B

81.12

2.96

1.6

Weighted average score

3.3

NAME

CURRENT

INDUSTRY

SCORE

Dividend yield

0.00

N/A

1.0

Payout ratio

0.00

N/A

1.0

5-year dividend growth rate

N/A

1.0

Years of dividend increase

N/A

1.0

Weighted average score

1.0

NAME

SCALE

SCORE

Market share

Medium

6.0

Intangible assets

Wide

8.0

Switching costs

Wide

8.0

Network effect

Narrow

2.0

Economies of scale

Medium

6.0

Weighted average score

6.0

Search stocks

Halozyme Therapeutics, Inc. (HALO)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Halozyme Therapeutics, Inc. (HALO)

Stock details

About the company

Revenue Breakdown

News

Chart: HALO

Overall Score

Octagon View

Strength & Weakness

Financial Strength

Debt to Assets

Financial

Current Ratio

Revenue & Net Income

Cashflow

Margin Ratios

Profitability

Net Margin

Effectiveness

Estimated EPS vs Actual EPS

Forecast

Analyst Rating

Growth

Revenue Growth Rate vs. Industry

Valuation

DCF Model

Dividend

Fair Value

$126.3

$101.915

Economic Moat

Stock details

About the company

Revenue Breakdown

News

Chart: HALO

Overall Score

Octagon View

Strength & Weakness

Financial Strength

Debt to Assets

Financial

Current Ratio

Revenue & Net Income

Cashflow

Margin Ratios

Profitability

Net Margin

Effectiveness

Estimated EPS vs Actual EPS

Forecast

Analyst Rating

Growth

Revenue Growth Rate vs. Industry

Valuation

DCF Model

Dividend

Fair Value

$126.3

$101.915

Economic Moat